Ps shouldn't it be purchased at the bottom....says it all |
Clive. It’s not an R@D company. It’s supposed to be a commercial company but has the revenues of an R@D company. And it is not about whether they are fighting a terrible disease, it’s about whether they are rinsing PIs. |
Nigel having the temerity to challenge his hero and mentor, a two bit failed trader tcurrently working as an ambulance driver.
Reminds me of the time CWA challenged Emptyhead and told him where to go! Empty has not been seen since! |
PATT - it's quite reasonable to state in June 2024 that you expect to start seeing revenue less cost in a period up to 18 months to expect cash breakeven.
That's very different from it actually happening.
They've still got 9 months to get there. |
5/6/24 RNS
“Completion of the fundraising, announced separately today, alongside delivery of market expectations is anticipated by the Company to secure cashflow breakeven on a monthly basis by the end of 2025”
26/9/24 RNS
“Revenues for the half-year of £1.0 million (H1 2023: £1.2 million)
- sold order book of up to £1.9 million at period end”
So the BoD are either liars as they fully knew that their booked H2 revenue was only £1.9m and how on earth would they expect cash breakeven, or they are deluded and utterly incompetent. Which one is worse? |
I don’t know if anyone posted the FDA list but it must have affected negotiations, partners would want assurances or evidence of future compliance if relevant to parsortix.
Stage 1:
By May 6, 2025, laboratories must comply with FDA lab developed test regulations for medical device reporting, corrections and removals reporting and complaint files.
Stage 2:
By May 6, 2026, laboratories must comply with FDA lab developed test regulations for facility registration and product listing, labeling and investigational uses of devices.
Stage 3:
By May 6, 2027, laboratories must comply with FDA’s quality system requirements for design controls, purchasing controls, acceptance activities, corrective and preventative actions and records.
Stage 4:
By November 6, 2027, laboratories must submit PMAs for high-risk tests.
Stage 5:
By May 6, 2028, laboratories must submit 510(k)s or De Novos for moderate-risk tests. |
 Purchase
The investors ignore the warnings.
At least AGL did warn about the pause in the sector funding plummeted and the FDA issue.
But still they made comments like funded into the 2nd half of 2026 indicating no more cash needed.
Still expecting £6.45m, 3 big names which by the AGM in reality was 1, and that 1 didn’t even amount to price sensitive news.
The FDA LDT point probably stalled any interest that may have been in play.
It’s Angle that are misleading investors NOT sober posters, looking at the numbers v claims.
Add in Trinity a couple of years ago £2.50/£2.20.
Good product but misleading hype by the company year after year.
They gambled last June didn’t raise enough, knowing the FDA issue, knowing the relevantvmarket had plummeted.
The reality is in the open offer they wanted £2m and got £500k.
And now this, needing probably £10m to £15m at least and soon.
Going back to backers where they made some exaggerated claims.
Backers that paid 80p before the 15p raise, where they reiterated £6.45m for 2024.
It could be a catastrophic raise in dilution terms in this market.
Hopefully the parsortix capability keeps that at bay, funding 6-8p or higher, if that rabbit finally appears from the hat.
Time is running short, market behaviour points to expectations of a raise very soon.
The quicker the better on this current trend.
You don’t want your be sitting at 6-8p with a few months cash left. |
Could force their hand to use Parsotix PATT |
"in retaliation for new U.S. tariffs.”
Trump strikes again! |
So like it or not they need a large cash injection soon and the most likely route is a fund raise.
Last time to achieve going concern they claimed into 2026 runway with some rather ambitious claims.
Rinse and repeat, investors are fed the same story.
If they raised £8.5m net again it’s just 6-7 months again, taking them to Q2 2026, with a raise again end of year.
They gambled like this last time and it was pointed out by posters. Instead of getting the full cash needed, they gambled on news.
No such news has come (yet).
Raised at 15p, CEO supposedly surprised at it dropping below 15p. That is highly naive but whoever posted that may be making it up.
Posts back then said 15p now 8p ish same amount £8.5m) later gives a 12p average, which is good.
And that on the balance is where it looks like it’s headed.
The only difference being 8p looks generous at this price and £8.5m not enough. |
It was impossible to state with certainty if Angle would hit the 6m revenue figure until it was formally announced - but, intuition led one to the view as tine went by that it was unlikely.
A similar theme is developing with tge pharma agreements. |
Well QED Yas. Its impossible to say what the status of these deal are. |
The point of these forums is to facilitate exchange of views - speculation, analysis and forecasting is part of that exercise. |
YasX - You're absolutely right in pointing out that "a seasoned investor knows that a company cannot disclose information that isn't publicly available." In my opinion, it would be wise to wait for an update from the company before making any comments on this board. Otherwise, any comments made here will be irrelevant. |
GS,
Of course the timelines are set by AZ - but logic dictates that by now if things were progressing well as claimed we ought to have heard something. If AZ are pursuing such trials and Angle remain silent then that is all we need to know. Not sure if that is the case as yet. |
Clive- No. Any seasoned investor knows a Co is unable to disclose information not in the public domain and, separately, a Co is invariably optimistic about its affairs. The only purpose of engaging a Co official (as I oft do) is to elicit bearish views by careful cross examination, certainly not to seek reassurance. Retail investors who lack such wisdom and skills ought to avoid engaging the Co. I do it but I know exactly what I am doing. |
yasXHave you attempted to address your concerns directly with AN or through their investor relations department? |
Borrowed from a tweet : |
Yas, when the pharma go to the next stage is not under ANs control… He will have to give them some space no matter how frustrating that may be for AGL/us. Nothing more off putting than an over-insistent, irritating partner.
(We’ve all had them 😆) |
goosey isn't that a bit old? |
Yas not so. If they are in talks then silence is also golden as any major deals would be cloaked in secrecy . All we can do is wait to see which of the possible outcomes it is .
I'm sure illumia will be looking to work with angle but on what basis remains to be seen .
Wether AN is upto his old tricks of putting all his eggs in one basket only for it to not work out as planned or keeping his options open with other clients who knows .
The biggest annoyance for me over recent years has been the amount of money spent whilst delivering very little . Costs should have been slashed well before they were given the lack of revenues
Losing 22m a year simply wasn't acceptable on any level given the lack of progress .
As you say it's getting very last chance saloon for agl and AN . Would t surprise me if it doesn't work out soon that he retires having failed to see it through .
he has collected plenty of salaries from shareholders but delivered next to nothing .
I don't know which outcome we will get here it's a pretty binary bet ,and how long before we find out is another unknown . What I do know with a good degree of certainty is another fund raise will arrive before results . Based on that I have my strategy |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
